Researchers analyzed data from 258 adults with MASLD, a condition involving fat buildup in the liver. The study looked at how the medication telmisartan affected various health markers, including blood sugar levels, body weight, and liver enzymes.
The analysis found that telmisartan led to a modest reduction in fasting blood sugar. However, the researchers noted that this specific finding should be interpreted with caution because the data across different studies was very inconsistent. Other markers, such as body mass index, waist circumference, and various liver health scores, showed no significant changes.
Because this was a meta-analysis of existing data, the results are not definitive for every patient. The small size of the effect on blood sugar and the high inconsistency in the data mean these findings are not yet enough to change standard medical practices. Patients should talk to their doctor about how these findings relate to their specific treatment plan.
